Evidence map›Paper›PMID 37111754›Full record

ArticlePharmaceutics2023

Biomimetic Boron Nitride Nanoparticles for Targeted Drug Delivery and Enhanced Antitumor Activity.

Hui Li, Wei Qiao, Yizhe Shen, Huashan Xu, Yuan Fan, Yuxiang Liu, Yadi Lan, Yan Gong, Fuxue Chen, Shini Feng

Abstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Synthesis of New Promising BNCT Agents Based on Conjugates ofInternational journal of molecular sciences · 2024
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hui LiSchool of Environmental and Chemical Engineering, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Wei QiaoSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Yizhe ShenSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Huashan XuSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Yuan FanSchool of Environmental and Chemical Engineering, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Yuxiang LiuSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Yadi LanSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Yan GongSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Fuxue ChenSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.
Shini FengSchool of Life Sciences, Shanghai University, 333 Nanchen Road, Shanghai 200444, China.ORCID 0000-0001-9225-067X

Funding

National Natural Science Foundation of China 52002239
6 · The paper itself

Abstract

Boron nitride nanomaterials are being increasingly recognized as vehicles for cancer drug delivery that increase drug loading and control drug release because of their excellent physicochemical properties and biocompatibility. However, these nanoparticles are often cleared rapidly by the immune system and have poor tumor targeting effects. As a result, biomimetic nanotechnology has emerged to address these challenges in recent times. Cell-derived biomimetic carriers have the characteristics of good biocompatibility, long circulation time, and strong targeting ability. Here, we report a biomimetic nanoplatform (CM@BN/DOX) prepared by encapsulating boron nitride nanoparticles (BN) and doxorubicin (DOX) together using cancer cell membrane (CCM) for targeted drug delivery and tumor therapy. The CM@BN/DOX nanoparticles (NPs) were able to target cancer cells of the same type on its own initiative through homologous targeting of cancer cell membranes. This led to a remarkable increase in cellular uptake. In vitro simulation of an acidic tumor microenvironment could effectively promote drug release from CM@BN/DOX. Furthermore, the CM@BN/DOX complex exhibited an excellent inhibitory effect against homotypic cancer cells. These findings suggest that CM@BN/DOX are promising in targeted drug delivery and potentially personalized therapy against their homologous tumor.

Indexed as

biomimeticboron nitridecancer cell membranedrug deliveryhomologous targeting

Identifiers

PMID37111754
PMCPMC10145272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.